Abstract: The application describes innovative designs for components of a drug transfer apparatus that overcome problems encountered in daily use of prior art apparatuses. Specifically described are components configured to prevent liquid from entering the air chamber of syringes coupled to the apparatus and to prevent tearing of the rubber stopper of drug vials when they are attached to the apparatus.

Abstract: A medicinal xiding vial, and a dispensing apparatus and an injection apparatus thereof, comprise a reversely pressed medicinal xiding vial, a reversely pressed dispensing apparatus and a reversely pressed injection apparatus thereof, a general medicinal xiding vial, and a general injection apparatus. The reversely pressed medicinal xiding vial comprises a vial body whose inner wall is a straight cylinder. A first piston is disposed on a position close to the vial opening of the vial body. A blind hole is disposed at the center of an outer bottom surface of the first piston. The vial opening is provided with an outer edge, and a seal cap is fixed on the out edge to prevent the first piston from falling off. In combination with the dispensing apparatus and the injection apparatus thereof, the medicinal xiding vial can solve the problem of secondary pollution during medicine dispensing and injection.

Abstract: A medication dispensing device comprises a cartridge unit and a control unit. The cartridge unit comprises a cartridge housing defining a dispensing channel to allow passage of the dosage from the cartridge to the patient. A cartridge holds dosages, with a driven member engaging the cartridge. The driven member drives the cartridge to dispense a dosage. The control unit comprises a main housing for coupling to the cartridge housing. A driver member engages the driven member to actuate the driven member. A motor driven locking mechanism is moveable between locked and unlocked positions. When in the locked position the cartridge unit is secured to the control unit. When in the unlocked position the cartridge unit is separable from the control unit thereby providing access to the cartridge. A mobile computing device stores dosage availability and receives an authorized patient identification input before dispensing a dosage.

Abstract: A micro electromechanical ink jet printing system that has a cartridge having a body that defines a core, and a die that contains one or more nozzles. There is a treatment composition contained within the cartridge core. The system further includes a CPU that is programmable and can control the application of the treatment composition from within the cartridge core, through the one or more nozzles to human skin. Typically, the treatment composition will contain a skin treatment ingredient selected from the group consisting of particles, vitamins, yeast and yeast extracts, skin care actives, dyes, colorants and mixtures thereof. There may optionally be provided a bladder or foam block disposed within the cartridge core for suspending and regulating the flow of the treatment composition. The systems of this invention may include an applicator having an applicator head having one or more applicator nozzles which may be in a array.

Abstract: A powder is disclosed including a first powder of core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water that includes a polar liquid having a percent surface polarity of at least 24%; and a shell comprising hydrophobic particles and a second powder including a color cosmetic.

Abstract: A treatment composition for treating human skin that has one or more particulate suspending agents in a concentration of from about 0.05% to about 2.0%, by weight, and one or more film forming polymers in a concentration of from about 0.1% to about 5.0%, by weight. Further, particles in a concentration of from about 1.0% to about 20.0%, by weight; one or more humectants in a concentration of from about 2.0% to about 20.0%, by weight; and, water are provided. The treatment compositions of this invention are used in an applicator having an applicator head having one or more applicator nozzles which may be in a array. The apparatus further has a reservoir containing the treatment composition, a sensor, and a CPU. The sensor takes an image of at least 10 ?m2 of skin, the CPU analyzes the image to calculate one or more localized L values of individual pixels or group of pixels of the skin. Then the CPU compares the local L value to a predetermined background L value to identify skin deviations.

Abstract: The invention relates to a cosmetic or dermatological composition which includes, in a physiologically acceptable medium, at least trans-resveratrol and/or at least one trans-resveratrol derivative, and an organic filtering system including at least one UVA filter and at least one UVB filter and/or at least one mixed UVA-UVB filter, said composition having an SPF no lower than 15 and a PPD no lower than 5. The invention also relates to a use of a filtering system which includes at least one UVA filter and at least one UVB filter and/or at least one mixed UVA-UVB filter for stabilising, in particular photostabilising, a composition including trans-resveratrol and/or at least one trans-resveratrol derivative.

Abstract: A composition directed to an aqueous hair leave-on composition for hair frizz reduction comprising from about 0.15% to about 12.0% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following class: Class I having the structure selected from: wherein R? is —COOY, sulfonic acid, or C?CH—COOY, Y is hydrogen or a metal ion, R1, R2, R3, R4, R5 is hydrogen, methyl, ethyl, propyl, vinyl, allyl, methoxy, ethoxy, hydroxyl, halogen, sulfate, sulfonate, nitro, or —CH?CH—COOR, and wherein the moisture control material is an acidic material and further wherein the moisture control material has a % Protein binding higher than 20 and Molecular Volume lower than 500 and Partition coefficient octanol to water (log P) lower than 3 and hydrogen binding higher than 10 and pKa lower than 5.0.

Abstract: A kit for coloring hair comprising: i) a first composition comprising an anionic surfactant, 2-amino-6-chloro-4-nitrophenol and a polyphenol; (ii) a second composition comprising a transition metal salt and/or complex.

Abstract: The present invention relates to a cosmetic or dermatological composition comprising, in a physiologically acceptable support: a) at least one merocyanine of formula (1) or (2). b) at least one oily phase comprising at least one amide compound of formula (I). The present invention also relates to a non-therapeutic cosmetic process for caring for and/or making up a keratin material, comprising the application, to the surface of the said keratin material, of at least one composition as defined above. The invention also relates to a non-therapeutic cosmetic process for limiting the darkening of the skin and/or improving the colour and/or uniformity of the complexion, comprising the application, to the surface of the keratin material, of at least one composition as defined previously.

Abstract: Provided are an internal olefin sulfonate composition which is capable of sufficiently enhancing foamability, foam spreadability, and foam dissipation property, and a cleansing composition containing the same. The internal olefin sulfonate composition comprises (A) an internal olefin sulfonate having 16 carbon atoms and (B) an internal olefin sulfonate having 14 carbon atoms, wherein a content mass ratio of the component (A) to the component (B), (A/B), is from 10/90 to 70/30, and a content of the internal olefin sulfonate having 18 or more carbon atoms is 5% by mass or less.

Abstract: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative, at least one dibenzoylmethane derivative and a cosmetic solvent selected from the group consisting of fatty acid triglycerides and/or sebacic acid esters or diesters. Furthermore, the invention relates to the use of at least one specific benzotriazol derivative for in creasing the water resistance of a dibenzoylmethane derivatives in a topical composition comprising a cosmetic solvent selected from the group consisting of fatty acid triglycerides and/or sebacic acid esters or diesters.

Abstract: A method for increasing muscular volume of a muscle in a human is provided. The method comprises injecting a composition comprising hyaluronic acid (HA) into one or more than one location of a muscle, thereby increasing the muscular volume as compared to before the injection. The muscle may be an arm, leg, chest, back or buttock muscle, or any other desired muscle. A method for altering a contour of a muscle in a human is also provided, which comprises obtaining an image of the contour of the muscle, determining a new contour, injecting an HA composition into one or more than one location of the muscle to obtain the new contour, thereby altering the contour as compared to before the injection. A use of a composition comprising HA for increasing muscular volume of a muscle in a human is also provided, where the composition is for injection into muscle.

Abstract: The present invention relates to an aqueous cosmetic composition which is in the form of a flexible solid, comprising: from 25% to 70% by weight of one or more anionic surfactants and one or more types of non-hollow solid particles, said composition comprising at least one anionic surfactant chosen from acylisethionates, preferably having an acyl group containing from 6 to 30 carbon atoms. Said composition is of preferential use as a composition for cleaning or washing keratin materials, in particular the hair. The invention also relates to a cosmetic treatment process, in particular for caring for, cleaning and/or conditioning keratin materials, using said composition.

Abstract: The present invention relates to a weakly acidic composition for skin external application, which comprises a pH adjuster, a polymeric thickener and a multi-lamellar emulsion and has a pH of 3-5, preferably 3-4.5, and to a cosmetic formulation comprising the composition. The multi-lamellar emulsion in the weakly acidic composition of the present invention contains large amounts of dermatologically useful oleophilic substances, has skin barrier function, and is stably maintained at a relatively low pH, and thus the composition normalizes the pH of the skin to enhance or restore the skin's barrier function to thereby restore and maintain the skin in a healthy state, and effectively moisturizes the skin. In addition, the composition is maintained at suitable viscosity so as to be effectively prevented from phase separation. Also, the composition does not penetrate the skin, and thus causes no skin irritation.

Abstract: A polymerizable nail coating composition includes a reactive (meth) acrylate monomer; a reactive (meth) acrylate terminated polymer selected from the group consisting of a reactive (meth) acrylate terminated polyol polymer, a reactive (meth) acrylate terminated polyester polymer, a reactive (meth) acrylate terminated polyol urethane polymer, a reactive (meth) acrylate terminated polyester polymer, and combinations thereof wherein said polymer is derived at least in part from a polyether or a polyester having either a melting point between 20° C. and 60° C. or a glass transition temperature between 20° C. and 60° C.; and a polymerization photoinitiator, wherein upon exposure to radiant energy, said polymerizable nail coating composition cures to a photocrosslinked polymer.

Abstract: A method of treating the hair including providing a concentrated hair care composition in an aerosol foam dispenser. The concentrated hair care composition includes one or more silicones, perfume, and less than 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the aerosol foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.40 g/cm3 when dispensed from the aerosol foam dispenser.

Abstract: A method of treating the hair including providing a concentrated hair care composition in a mechanical foam dispenser. The concentrated hair care composition includes one or more silicones, from about 1% to about 5% perfume, and is substantially free of high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the mechanical foam dispenser as a dosage of foam; applying the foam to the hair; and rinsing the foam from the hair. The foam has a density of from about 0.025 g/cm3 to about 0.3 g/cm3 when dispensed from the mechanical foam dispenser.

Abstract: A method of treating the hair including providing a concentrated hair care composition in a dispenser. The concentrated hair care composition includes one or more silicones, perfume, and from about 2% to about 10% high melting point fatty compounds. The method also includes dispensing the concentrated hair care composition from the dispenser, applying the concentrated hair care composition the hair; and rinsing the concentrated hair care composition from the hair.

Abstract: A method of treating the hair including providing a pre-aerated concentrated hair care composition. The pre-aerated concentrated hair care composition includes one or more silicones, perfume, and from about 2% to about 10% high melting point fatty compounds. The method also includes applying the pre-aerated concentrated hair care composition the hair; and rinsing the pre-aerated concentrated hair care composition from the hair. The pre-aerated concentrated hair care composition has a density of from about 0.15 g/cm3 to about 0.75 g/cm3 when dispensed from the aerosol foam dispenser.

Abstract: A lip treatment composition for creating a perceptible tingling sensation when applied to mucosa membrane of a user. The composition has one or more base ingredients and at least one active ingredient, such as Zanthoxylum essential oil, that induces a perceptible tingling sensation reminiscent of electrical buzzing when applied to the mucosa membrane of the user. The Zanthoxylum essential oil could comprises between approximately 2.0000% and 4.0000% by weight of the composition and could comprise approximately 3.3000% by weight of the composition. The lip treatment composition can be formed under a process including heating the one or more base ingredients, adding the at least one active ingredient, and mixing the one or more base ingredients and the at least one active ingredient.

Abstract: Methods of using extracts of Basella alba to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin.

Abstract: Methods of using extracts of Phyllanthus acidus to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin. The present invention relates generally to compositions for topical application to the skin which comprise extracts of Phyllanthus acidus and the use of such compositions to provide benefits to the skin, in particular, aesthetic improvement, anti-aging, anti-cellulite, skin lightening, and/or anti-wrinkle benefits.

Abstract: The present invention is directed to methods of using extracts of Vernonia cinerea to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin, by increasing glycosaminoglycan production and/or content. The present invention is further directed to a composition for providing an aesthetic improvement of the skin comprising an effective amount of a second aqueous extract of a butanol/water extract of Vernonia cinerea and a cosmetically acceptable vehicle, in the form of a water-in-oil, oil-in-water, silicone-in-water, water-in-silicone, polyol-in-silicone, or silicone-in-polyol emulsion.

Abstract: The invention relates to a cosmetic composition comprising at least one extract from the orchid Dendrobium chrysotoxum as an active agent and at least one cosmetically acceptable excipient. The invention relates to the use in a cosmetic composition of an extract from the orchid Dendrobium chrysotoxum as an active agent for preventing or delaying the appearance of the signs of skin ageing or for slowing or attenuating the effects thereof, or else also for promoting cell or tissue longevity. The invention in particular relates to an orchid extract inhibiting the expression and/or the activity of the mitochondrial protein Smac/DIABLO.

Abstract: Formulations to treat skin discoloration via a multi-modal approach are provided in which select ingredients work together to effectively brighten skin and treat hyperpigmentation. An example formulation includes a first anti-melanin agent, a second anti-melanin agent, an anti-inflammatory agent, a sun protection agent, and an anti-oxidant. In one aspect, the first anti-melanin agent comprises a bidens pilosa extract, the second anti-melanin agent comprises a rheum rhaponticum extract, the anti-inflammatory agent comprises a Vitamin E compound, the sun protection agent comprises zinc oxide and titanium dioxide, and the antioxidant comprises a thermus thermophilus ferment extract.

Abstract: The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.

Abstract: Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.

Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Abstract: Provided herein are methods of locally and specifically anesthetizing nerve tissue in the trigeminal nerve pathway and methods of performing a surgical procedure on a subject in need thereof that include intranasally administering (1) a pharmaceutical composition that includes a local anesthetic agent and a mucosal absorption enhancer to a subject in need thereof, where the local anesthetic agent and mucosal absorption enhancer are present in an amount sufficient to anesthetize nerve tissue in the trigeminal nerve pathway upon administration, or (2) a pharmaceutical composition that include a free-base form of a local anesthetic agent, where the free-base form of the local anesthetic agent is present in an amount sufficient to anesthetize nerve tissue in the trigeminal nerve pathway upon administration.

Abstract: The present invention is directed to an edible film that contains two or more segmented portions and comprises an active ingredient that is distributed on a segmented portion or portions which comprise less than 50% of the cross sectional surface area of a major face of said film. The present invention also relates to methods of treatment for the treatment of various conditions and for taste-masking of pharmaceutical ingredients.

Abstract: A compounded transdermal cream may include gabapentin, diclofenac, cyclobenzaprine, or a combination thereof. The compounded transdermal cream may further include lidocaine in an amount between approximately 0.5% to approximately 5.0% by weight of the compounded transdermal cream and prilocaine in an amount between approximately 0.5% to approximately 5.0% by weight of the compounded transdermal cream.

Abstract: Irregular, angular particles are produced by a manufacturing method that comprises forming a film on a substrate and then stretching the substrate along one or more axes to fracture the film into particle structures. The substrate may be moved continuously along a production line as the film is formed and may be stretched by accelerating that movement. The substrate may comprise a surface with elevated patterns to control the fracturing of the film. The particles are particularly suitable for the transdermal delivery of a biologically active substance into the body of a patient.

Abstract: A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes a polar liquid having a percent surface polarity of at least 24% and a shell comprising hydrophobic particles; and at least one second powder comprising a benefit agent. The powder can be used to topically administer the active ingredient to a human or animal.

Abstract: The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.

Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Abstract: Method for producing sodium bicarbonate particles by spray-drying of an aqueous solution comprising 1 to 10% by weight of sodium bicarbonate and an additive selected from the group consisting of: magnesium salt, sodium alkylbenzene sulfonate and soybean lecithin. Sodium bicarbonate particles obtainable by such process and comprising at least 20 mg of the additive per kg of sodium bicarbonate particles.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.

Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.

Abstract: The invention provides novel formulations of guanylate cyclase-C(“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.

Abstract: Provided is a positioning immediate-release bioadhesive and relates to a medical device for preventing or/and treating diabetes, obesity, alcoholism, gastric and intestinal mucosal inflammation or/and ulcers and the like. The positioning immediate-release bioadhesive is prepared by preparing a biocompatible bioadhesive material into micro-particles, externally adding an immediate-release disintegrant, tabletting and then performing enteric or gastric coating; or performing enteric or gastric coating on the micro-particles; or filling into enteric-coated or gastric-coated hollow capsules; or directly tabletting the bioadhesive material, the immediate-release disintegrant and other additional agents and then performing enteric or gastric coating.

Abstract: Disclosed are gas-generating nanoparticles comprising fine-grained calcium carbonate crystals and a biocompatible polymer, the fine-grained calcium carbonate crystals being encapsulated inside the biocompatible polymer, and the diagnosis and treatment of diseases can be effectively performed at the same time by using a composition of the present disclosure.

Abstract: The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein. In illustrative embodiments, polymer components of the shell are interconnected by peptide-containing crosslinker moieties, linkages which maintain the integrity of the polymer shell under certain environmental conditions, but can also be cleaved when combined with a selected protease.

Abstract: A composition is provided comprising: (i) menthol, and (ii) a carrier comprising a digestible edible oil, wherein said digestible edible oil is one that provides a composition which is a liquid at 20° C. after rising to that temperature from a lower temperature at which the oil was previously semisolid. The preferred edible oil is a medium-chain triglyceride oil, wherein the level of menthol in the composition is between 1-50% by total weight, so as to provide an menthol application rate of between 5 and 20 mg of menthol, and most preferably, about 10 mg menthol, in a single droplet of the composition. The composition can also include additional added vitamins and essential oils. A liquid method for administering menthol is provided.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: There is disclosed herein a method of improving the wellbeing, as herein defined, of an animal comprising administering to an animal an effective amount of a composition containing: vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, excipient and/or diluent.

Abstract: Disclosed in the present invention is new use of saturated amine compounds for use in preparing medicines to resist radiation damage and promoting regeneration and repair of radiation-damaged tissues.